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Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis 
Homozygous for Phe508del CFTR
To the Editor: With regard to the article by 
Wainwright et al. (July 16 issue),1 randomized 
trials evaluating the efficacy of lumacaftor, iva-
caftor, or both have included only a limited num-
ber of patients with a forced expiratory volume in 
1 second (FEV1) at baseline of less than 40% of 
the predicted value. Only 52 patients in the 
TRAFFIC and TRANSPORT trials and none of the 
patients in several other studies had this low per-
centage of predicted FEV1 at baseline.
2,3 Since the 
majority of patients in resource-limited countries 
receive a diagnosis of cystic fibrosis later in 
childhood (when the disease might be advanced), 
the efficacy of lumacaftor–ivacaftor therapy in 
patients with poor pulmonary function needs to 
be evaluated further.
Moreover, the current cost of lumacaftor–iva-
caftor therapy is almost $300,000 per year; this is 
much higher than the cost of conventional ther-
apy, which is less than $300 per year. Since the 
magnitude of change observed with lumacaftor–
ivacaftor therapy was “in the range of the mag-
nitudes of change seen in studies of other cystic 
fibrosis therapeutics,”1 the cost-effectiveness of 
this form of therapy should be evaluated.4
Finally, in some regions of the world, the 
Phe508del CFTR mutation is uncommon (e.g., 
one study5 showed that only 26.9% of patients 
with cystic fibrosis in the United Arab Emirates 
are homozygous for this allele). For these pa-
tients, conventional therapy (hypertonic saline, 
azithromycin, or ibuprofen) remains the treat-
ment of choice.
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The Authors Reply: We agree with Rehman 
et al. that more trials that include patients with 
lower lung function are warranted. In the clinical 
trials on which we reported, the response to luma-
caftor–ivacaftor was independent of the percent-
age of predicted FEV1 at baseline. A subsequent 
post hoc analysis involving patients with an FEV1 
of less than 40% of the predicted value at ran-
domization, as compared with those with an 
FEV1 of 40% or more of the predicted value, 
showed similar benefits with respect to FEV1 and 
pulmonary exacerbations.1 An open-label trial of 
lumacaftor–ivacaftor involving patients with an 
FEV1 of less than 40% of the predicted value is on-
going (ClinicalTrials.gov number, NCT02390219).
Lumacaftor–ivacaftor and ivacaftor are very 
expensive; however, the estimated cost of $300 
per annum for “conventional” therapies that 
Rehman and colleagues suggest is incorrect. 
Dornase alfa, inhaled antibiotic agents, pancre-
atic enzymes, and hospital admissions for pulmo-
nary exacerbations — all of which are considered 
to be conventional therapy — cost substantially 
more. Once longer-term treatment benefits are 
understood, cost-effectiveness may be evaluated 
with the use of methods that are appropriate for 
rare diseases.
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A Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
To the Editor: In reporting on the Lutonix Pac-
litaxel-Coated Balloon for the Prevention of 
Femoropopliteal Restenosis (LEVANT) 2 trial, 
Rosenfield et al. (July 9 issue)1 suggest that an-
gioplasty with a paclitaxel-coated balloon, as 
compared with angioplasty with a standard bal-
loon, provided superior vessel patency in patients 
with femoropopliteal disease at 12 months. Al-
though these results are encouraging, it is un-
clear whether superior vessel patency translates 
into improvements in more clinically appropriate 
end points such as ambulatory function and 
quality of life.2
The majority of the patients in the trial (92%) 
had moderate intermittent claudication (Ruther-
ford stage 2) or severe intermittent claudication 
(Rutherford stage 3) (the Rutherford scale ranges 
from 0 to 6, with higher numbers indicating 
worse disease), with single, short lesions of the 
superficial femoral artery. Yet, the primary end 
point of freedom from binary restenosis or target-
lesion revascularization occurred in only 65% of 
the intervention cohort and 53% of controls. The 
clinical significance of this difference is unclear, 
and this lack of clarity highlights the need to 
design trials that are powered to show the ef-
fectiveness of endovascular interventions for the 
clinical outcomes of femoropopliteal disease, such 
as improvements in symptoms of claudication.3 
In the meantime, enthusiasm for techniques such 
as this one must be curbed.
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To the Editor: In the LEVANT 2 trial, Rosen-
field et al. found lower rates of restenosis and a 
decreased need for target-lesion revasculariza-
tion among patients with symptomatic femoro-
popliteal peripheral artery disease after angio-
plasty with the use of a paclitaxel-coated balloon 
than with a standard balloon. The clinical char-
acteristics, history of coexisting conditions, and 
antiplatelet regimen were similar between the 
treatment groups. However, the authors did not 
provide information regarding other treatments 
to prevent cardiovascular disease, particularly 
statin therapy. Were statins used with equal fre-
quency in the randomized groups? If not, we be-
lieve that stratification according to the use or 
nonuse of statin therapy would be appropriate 
because of its possible confounding effects on 
the efficacy of angioplasty.
 Indeed, statins are associated with improved 
lesion patency among patients who have under-
gone endovascular treatment.1,2 They are also 
associated with better outcomes with respect to 
the rate of salvage of ischemic limbs among 
patients with peripheral artery disease.2-4 More-
over, statins reduce the risk of major cardiovas-
cular events and death among such patients.1,2,4 
On the basis of  these findings, the guidelines 
of the American College of Cardiology Founda-
tion and the American Heart Association recom-
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